middle.news
OncoSil Medical Dose Sales Surge 60 Percent as Key Trials Progress
10:18am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
OncoSil Medical Dose Sales Surge 60 Percent as Key Trials Progress
10:18am on Tuesday 28th of April, 2026 AEST
Key Points
60% increase in dose sales year-on-year
56% growth in commercially active centres
Germany G-BA trial set to start in Q4 FY26
Operational cost savings of $3.4-3.9 million annualised
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE